Top

Published in:

01-04-2005 | Therapy in Practice

Treatment of Legionnaires’ Disease

Author: Dr Guy W. Amsden

Published in: Drugs | Issue 5/2005

Abstract

Legionnaires’ disease is pneumonia, usually caused by Legionella pneumophila, which can range in severity from mild to quite severe. While it is commonly acquired in the community, it can just as easily be acquired nosocomially from water sources that have not been appropriately decontaminated. While historically initial treatment was always with erythromycin, current case series and treatment recommendations suggest that outpatients receive immediate treatment with one of the following antibacterials: azithromycin, erythromycin, clarithromycin, telithromycin, doxycycline or an extended-spectrum fluoroquinolone. If the symptoms are severe enough to warrant hospitalisation then the patient should receive treatment with parenteral azithromycin or extended-spectrum fluoroquinolones followed by step-down to oral formulations to complete the regimens. While a shorter course of 7–10 days for more severe infections may be possible for intravenous/oral azithromycin, other antibacterials should be administered for a total of 10–21 days and started as soon as possible upon presentation to optimise outcomes.

Fraser DW, Tsai TR, Ovenstein W, et al. The field investigation team. Legionnaires’ disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297: 1189–97

Terranova W, Cohen ML, Fraser DW. Outbreak of Legionnaires’ disease diagnosed in 1977. Lancet 1978; 2: 122–4PubMedCrossRef

Osterholm MT, Chin TD, Osborne DO, et al. A 1957 outbreak of Legionnaires’ disease associated with a meat packing plant. Am J Epidemiol 1983; 117: 60–7PubMed

Marrie TJ, Peeling RW, Fine MJ, et al. Ambulatory patients with community-acquired pneumonia: The frequency of atypical agents and clinical course. Am J Med 1996; 101: 508–15PubMedCrossRef

Stout JE, Yu VL. Current Concepts: Legionellosis. N Engl J Med 1997; 337: 682–7PubMedCrossRef

Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69: 307–16

Torres A, Sera-Batilles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312–8PubMedCrossRef

Yu VL. Legionella pneumophila (Legionnaires’ disease). In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2424–35

Camerson S, Walker C, Roden D, et al. Epidemiological characteristics of Legionella infection in South Australia: implications for disease control. Aust N Z Med 1991; 21: 65–70CrossRef

10.

Muder RR. Other Legionella species. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia (PA): Churchill Livingstone, 2000: 2435–41

11.

Fang GD, Yu VL, Vickers RM. Disease due to Legionellaceae (other than Legionella pneumophila): historical, microbiological, clinical and epidemiological review. Medicine (Baltimore) 1989; 68: 116–39CrossRef

12.

Best M, Yu VL, Stout J, et al. Legionellaceae in the hospital water supply: epidemiological link with disease and evaluation of a method of control of nosocomial legionnaires’ disease and Pittsburgh pneumonia. Lancet 1983; 2: 307–10PubMedCrossRef

13.

Roig J Rello J. Legionnaires’ disease: a rational approach to therapy. J Antimicrob Chemother 2003; 51: 1119–29CrossRef

14.

Mandell LA, Bartlett JG, Dowell SF, et al. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; 37: 405–33

15.

Friedman H, Yamamoto Y, Klein TW. Legionella pneumophila pathogenesis and immunity. Sem Pediatr Infect Dis 2002; 13: 273–9CrossRef

16.

Stout JE, Lin YSE, Goetz AM, et al. Controlling Legionella in hospital water systems: experience with the superheat-and-flush method and copper-silver ionization. Infect Control Hosp Epidemiol 1998; 19: 911–4PubMedCrossRef

17.

Dedicoat M, Venkatesan P. The treatment of Legionnaires’ disease. J Antimicrob Chemother 1999; 43: 747–52PubMedCrossRef

18.

Smith GM Sutherland. Activity of amoxycillin-clavulanic acid against Legionella pneumophila in vitro and in an experimental respiratory infection model. J Hosp Infect 1992; 22 Suppl. A: 61–7PubMedCrossRef

19.

Smith GM, Abbott KH, Sutherland R. Bactericidal effects of coamoxiclav (amoxycillin clavulanic acid) against a Legionella pneumophila pneumonia in the immunocompromised weanling rat. J Antimicrob Chemother 1992; 30: 525–34PubMedCrossRef

20.

Stokes DH, Wilkinson MJ, Tyler J, et al. Bactericidal effects of amoxycillin/clavulanic acid against intracellular Legionella pneumophila in tissue culture studies. J Antimicrob Chemother 1989; 23: 547–56PubMedCrossRef

21.

Smith GM, Abbott KH, Wilkinson MJ, et al. Bactericidal effects of amoxycillin/clavulanic acid against a Legionella pneumophila pneumonia in the weanling rat. J Antimicrob Chemother 1991; 27: 127–36PubMedCrossRef

22.

Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1–10PubMedCrossRef

23.

Zimmerman T, Riedel KD, Laufen H, et al. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromycin [abstract no. A82]. In: Abstracts of the 36^th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans (LA): American Society for Microbiology, 1996: 16

24.

Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe Legionnaire’s disease. J Antimicrob Chemother 1990; 26 Suppl. B: 129–39PubMedCrossRef

25.

Hubbard RB, Mathur RM, MacFarlane JT. Severe community acquired legionella pneumonia: treatment, complications and outcome. Quart J Med 1993; 86: 327–32PubMed

26.

Rello J, Bodi M, Mariscal D, et al. Microbiological testing and outcome of patients with severe community-acquired pneumonia. Chest 2003; 123: 174–80PubMedCrossRef

27.

Tan MJ, Tan JS, File Jr TM. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35: 533–9PubMedCrossRef

28.

Hamedani P, Ali J, Hafeez S, et al. The safety and efficacy of clarithromycin in patients with legionella pneumonia. Chest 1991; 100: 1503–6PubMedCrossRef

29.

Kuzman I, Soldo I, Schönwald S, et al. Azithromycin for treatment of community acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995; 27: 503–5PubMedCrossRef

30.

Plouffe JF, Breiman RF, Fields BS, et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin Infect Dis 2003; 37: 1475–80PubMedCrossRef

31.

Carbon C, Nusrat R. Efficacy of telithromycin in community-acquired pneumonia caused by Legionella pneumophila. Eur J Clin Microbiol Infect Dis 2004; 23: 650–2PubMedCrossRef

32.

Santos J, Aguilar L, Garcïa-Méndez E, et al. Clinical characteristics and response to newer quinolones in Legionella pneumonia: a report of 28 cases. J Chemother 2003; 15: 461–5PubMed

33.

Dorrell L, Fulton B, Ong ELC. Intravenous azithromycin as salvage therapy in a patient with Legionnaire’s disease. Thorax 1994; 49: 620–1PubMedCrossRef

34.

Matute AJ, Schurink CAM, Hoepelman IM. Is a 5 day course of azithromycin enough for infections caused by Legionella pneumophila? J Antimicrob Chemother 2000; 45: 919–31CrossRef

35.

Edelstein PH, Shinzato T, Doyle E, et al. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother. 2001; 45: 2204–9CrossRef

36.

Edelstein PH, Edelstein MAC, Ren J, et al. Activity of trovafloxacin (CP-99,219) against Legionella isolates: in vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996; 40: 314–9

37.

Dubois J, St-Pierre C. In vitro activity of gatifloxacin compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. Diagn Microbiol Infect Dis 1999; 33: 261–5PubMedCrossRef

38.

Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antibiotic therapy. Intensive Care Med 2002; 28: 686–91PubMedCrossRef

39.

Lettinga KD, Verbon A, Weverling G-J, et al. Legionnaires’ disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002; 8: 1448–54PubMedCrossRef

40.

Edelstein PH, Cianciotto NP. Legionella. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 6th ed. Philadelphia (PA): Churchill Livingstone, 2004: 2711–24

Title: Treatment of Legionnaires’ Disease
Author: Dr Guy W. Amsden
Publication date: 01-04-2005
Publisher: Springer International Publishing
Published in: Drugs / Issue 5/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.2165/00003495-200565050-00003

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Treatment of Legionnaires’ Disease

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2005

Gatifloxacin

Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease

Contraceptive Vaccines

Efficacy, Tolerability and Cost Effectiveness of Disease-Modifying Antirheumatic Drugs and Biologic Agents in Rheumatoid Arthritis

Amprenavir or Fosamprenavir plus Ritonavir in HIV Infection

Combating Chronic Renal Allograft Dysfunction